Treatment
Cyclophosphamid clinical trials
We’re tracking 517 recruiting studies that include Cyclophosphamid, each written for real people, not researchers, below.
Recruiting studies
- NCT06361329RecruitingPhase 3
Comparing new drug combo to standard chemo for ETP-ALL
This trial compares a new combination of drugs (venetoclax plus chemotherapy) to standard chemotherapy for people newly diagnosed with a rare type of T-cell leukemia called ETP-ALL. The goal is to see if the new regimen works better.
Hangzhou, ZhejiangAges 14–75 - NCT07389239RecruitingPhase 1/Phase 2
Immunotherapy for ovarian cancer and other advanced tumors
This study tests an immunotherapy treatment for people with advanced solid tumors, including ovarian cancer, sarcoma, prostate, breast, lung, and others. It is designed for tumors that show a specific marker called NY-ESO-1, and aims to see if the treatment can help shrink or control the cancer.
Chicago, IllinoisAges 18 years+ - NCT07390539RecruitingPhase 1
CAR T cells targeting B7-H3 for brain tumors
This trial tests a new type of immune therapy (CAR T cells) that targets a protein called B7-H3 found on some brain tumors. It is for children and young adults with certain brain or spinal cord tumors that have come back after standard treatment, and aims to see if the treatment is safe and effective.
Boston, MassachusettsAges 2–21 - NCT06564493RecruitingPhase 2
Radiation conditioning before sibling stem cell transplant for pediatric ALL
This study tests two types of radiation-based conditioning (TBI or TMLI) before a stem cell transplant from a matched sibling donor, in children with ALL that is in remission. The goal is to see which approach works better and is safer.
Zhengzhou, HenanAges 1–17 - NCT06557161RecruitingPhase 2
Stem cell transplant with TBI or TMLI for adult ALL
This trial tests two different conditioning regimens (total body irradiation or total marrow/lymphoid irradiation) before a stem cell transplant from a matched sibling donor for adults with acute lymphoblastic leukemia (ALL) that is in remission. The goal is to see which regimen works better and has fewer side effects.
Zhengzhou, HenanAges 18–65 - NCT06559345RecruitingPhase 2
Stem cell transplant study for children with ALL in remission
This trial tests a stem cell transplant using a half-matched family donor for children with acute lymphoblastic leukemia (ALL) that is in remission. It compares two different types of radiation conditioning to prepare the body for the new cells, with the goal of improving outcomes.
Zhengzhou, HenanAges 1–17 - NCT06564545RecruitingPhase 2
Radiation-based transplant preparation for adult ALL
This trial studies a new way to prepare adults with ALL for a stem cell transplant from a half-matched family donor. It compares two types of radiation-based conditioning to see which works better and has fewer side effects.
Zhengzhou, HenanAges 18–65 - NCT06299462RecruitingPhase 1/Phase 2
Preventing GVHD with PTCy and ATG in stem cell transplant
This trial tests a combination of two drugs (PTCy and ATG) to prevent graft-versus-host disease after a stem cell transplant from a matched donor. It is for adults with certain blood cancers who are between 18 and 60 and have a suitable donor.
Rio de Janeiro, Rio de JaneiroAges 18–60 - NCT07362914RecruitingPhase 3
Steroid cream for hand-foot skin reactions from chemo
This trial tests whether a corticosteroid cream can prevent or reduce hand-foot skin reactions caused by liposomal doxorubicin (a type of chemotherapy) in breast cancer patients. If you are starting this chemo and are concerned about skin side effects, this study may offer a way to manage them.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05020860RecruitingPhase 2
Study how early breast cancer responds on imaging and under a microscope
This Phase 2 study looks at how well early breast cancer shrinks with treatment and how that matches with what doctors find after surgery under the microscope. The goal is to learn better ways to predict and assess treatment success.
Houston, TexasAges 18 years+ - NCT07358260RecruitingPhase 1
B7-H3 CAR T cells for solid tumors in children and young adults
This trial tests a new type of immune cell therapy called CAR T cells that target a protein called B7-H3 found on many solid tumors. It is for children and young adults whose cancer has come back or stopped responding to standard treatments.
Boston, MassachusettsAges 9 months–30 years - NCT07359859RecruitingPhase 2
Ruxolitinib to prevent GVHD in stem cell transplant
This trial tests whether the drug ruxolitinib, given before and after a stem cell transplant, can help prevent graft-versus-host disease (GVHD) in people with blood cancers. GVHD is a common complication where donor cells attack the patient's body.
Basking Ridge, New JerseyAges 18 years+ - NCT07341867RecruitingPhase 1
Dose changes for cancer treatment in people with Duffy null
This trial tests if changing the dose of certain chemotherapy drugs can help people with a genetic trait called Duffy null avoid side effects like low white blood cell counts. It is for people with multiple myeloma or triple-negative breast cancer starting specific treatments.
Boston, MassachusettsAges 18 years+ - NCT07328503RecruitingPhase 2
CD22 CAR T-cells to prevent relapse after CD19 CAR T-cell therapy
This trial tests if giving a second type of CAR T-cell therapy that targets CD22 can help keep B-cell acute lymphoblastic leukemia (ALL) in remission for people who are already in remission after CD19 CAR T-cell treatment. It aims to reduce the risk of the cancer coming back.
Bethesda, MarylandAges 3–65 - NCT07321912RecruitingPhase 2
Eflornithine (DFMO) for Ewing sarcoma and osteosarcoma
This trial tests a drug called eflornithine (DFMO) for people with Ewing sarcoma or osteosarcoma that has come back or spread. The goal is to see if DFMO can help control the cancer after standard treatment.
Tampa, FloridaAges birth–50 years - NCT07308132RecruitingPhase 1
Study of a new drug for B-cell lymphoma
This study tests an experimental drug for people with B-cell non-Hodgkin lymphoma (a type of blood cancer) that has come back or hasn't responded to standard treatments. The goal is to see if the drug is safe and can shrink the cancer.
ClaytonAges 18 years+ - NCT07297667RecruitingPhase 1
CAR T-cell therapy for certain advanced solid tumors
This trial tests a new treatment called GCAR1, which uses your own immune cells (T-cells) to find and attack cancer cells that have a specific marker called GPNMB. It is for people with certain advanced solid tumors that have not responded to other treatments. The goal is to see if this therapy can help shrink or control the tumor.
Calgary, AlbertaAges 15 years+ - NCT07304154RecruitingPhase 1
Study of KITE-363 for autoimmune nerve diseases
This trial tests a new treatment called KITE-363 for people with certain autoimmune nerve diseases, such as multiple sclerosis, myasthenia gravis, or chronic inflammatory demyelinating polyneuropathy, that have not responded well to standard therapies. The goal is to see if it is safe and effective.
Newport Beach, CaliforniaAges 18–75 - NCT07288073RecruitingPhase 2
TIL Therapy for Advanced Skin Cancer Patients
This study tests a personalized cell therapy called TIL (tumor-infiltrating lymphocytes) for people with advanced skin cancers that have not responded to immunotherapy. Doctors take your tumor cells, grow immune cells from them, and then infuse them back to fight the cancer.
Boston, MassachusettsAges 18 years+ - NCT07284433RecruitingPhase 1/Phase 2
Donor cell therapy for B-cell blood cancers
This trial tests a new treatment made from donor cells that target two proteins (CD19 and CD20) found on certain blood cancer cells. It may be an option for people whose B-cell lymphoma or chronic lymphocytic leukemia has come back or hasn't responded to at least two prior treatments.
Chicago, IllinoisAges 18 years+ - NCT07278856RecruitingPhase 1
Ruxolitinib plus CHOP for untreated T-follicular helper cell lymphoma
This trial tests adding an oral targeted drug called ruxolitinib to the standard CHOP chemotherapy for people newly diagnosed with a rare type of lymphoma. The goal is to see if this combination is safe and works well.
Duarte, CaliforniaAges 18 years+ - NCT07255664RecruitingPhase 1/Phase 2
TIL therapy for advanced colorectal or prostate cancer
This trial tests a new type of immunotherapy that uses your own white blood cells (TILs) to fight advanced colorectal or prostate cancer. You will have surgery to remove a tumor, then your TIL cells are grown in a lab and given back to you along with other treatments to boost your immune system.
FrankfurtAges 18 years+ - NCT07258680Enrolling by invitationPhase 3
Testing brentuximab and etoposide for T-cell lymphoma
This trial tests whether adding the drugs brentuximab and etoposide to standard chemotherapy improves treatment for people newly diagnosed with T-cell lymphoma. It aims to find a more effective first treatment option.
Ages 18–70 - NCT07257419RecruitingPhase 1
CAR T cells and stem cell transplant for leukemia and lymphoma
This trial tests giving special immune cells (CAR T cells) after a half-matched stem cell transplant. It's for children and young adults with high-risk leukemia or lymphoma that has come back or not responded to treatment.
Memphis, TennesseeAges Up to 21 years
Common questions
- Are there clinical trials studying Cyclophosphamid?
- Yes. Clin2 currently lists 517 recruiting studies that include Cyclophosphamid, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cyclophosphamid trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cyclophosphamid an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cyclophosphamid or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.